Taken together with the notion that ERα acts as a master transcription factor in endometrial cancers [28], aberrant CLDN6 signaling may promote the malignant behavior of endometrial cancer cells via hijacking the CLDN6–ERα pathway. This evidence concerns the gene CLDN6 and endometrial cancer.